Short-term drop in antibody titer after the third dose of SARS-CoV-2 BNT162b2 vaccine in adults

  1. Jonas Herzberg
  2. Bastian Fischer
  3. Heiko Becher
  4. Ann-Kristin Becker
  5. Human Honarpisheh
  6. Salman Yousuf Guraya
  7. Tim Strate
  8. Cornelius Knabbe
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Little is known about the longevity of antibodies after a third dose of BNT162b2 (BioNTech/Pfizer). Therefore, the serum antibody levels were evaluated after the third dose of BNT162b2 which dropped significantly within 11 weeks from 4155.59 ± 2373.65 BAU/ml to 2389.10 ± 1433.90 BAU/ml, p -value <0.001 but remained higher than after the second dose.

These data underline the positive effect of third dose of BNT162b2 but shows a rapid and significant drop of antibodies within a short span of time.

Trial Registration

This trial was prospectively registered in the German Clinical Trial Register (DRKS00021270).

Related articles

Related articles are currently not available for this article.